EUVIMEDEUVIMED entdecken
Open Access

Benign Breast Disease and Breast Cancer Risk in the Percutaneous Biopsy Era

Mark E Sherman, Robert A Vierkant, Stacey J Winham, Celine M Vachon, Jodi M Carter, Laura Pacheco-Spann, Matthew R Jensen, Bryan M McCauley, Tanya L Hoskin, Lisa Seymour, Denice Gehling, Jessica Fischer und 3 weitere

JAMA Surgery · 01.02.2024 · 159 (2) · 193

DOI: 10.1001/jamasurg.2023.6382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Surgery, erschienen am 01.02.2024. Verfasst von Mark E Sherman und 14 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida. Hauptthemen laut MEDLINE: Breast Neoplasms, Breast Diseases, Carcinoma, Intraductal, Noninfiltrating, Precancerous Conditions. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Benign breast disease (BBD) comprises approximately 75% of breast biopsy diagnoses. Surgical biopsy specimens diagnosed as nonproliferative (NP), proliferative disease without atypia (PDWA), or atypical hyperplasia (AH) are associated with increasing breast cancer (BC) risk; however, knowledge is limited on risk associated with percutaneously diagnosed BBD.

Objectives

To estimate BC risk associated with BBD in the percutaneous biopsy era irrespective of surgical biopsy. Design, Setting, and Participants In this retrospective cohort study, BBD biopsy specimens collected from January 1, 2002, to December 31, 2013, from patients with BBD at Mayo Clinic in Rochester, Minnesota, were reviewed by 2 pathologists masked to outcomes. Women were followed up from 6 months after biopsy until censoring, BC diagnosis, or December 31, 2021. Exposure Benign breast disease classification and multiplicity by pathology panel review. Main Outcomes The main outcome was diagnosis of BC overall and stratified as ductal carcinoma in situ (DCIS) or invasive BC. Risk for presence vs absence of BBD lesions was assessed by Cox proportional hazards regression. Risk in patients with BBD compared with female breast cancer incidence rates from the Iowa Surveillance, Epidemiology, and End Results (SEER) program were estimated.

Results

Among 4819 female participants, median age was 51 years (IQR, 43-62 years). Median follow-up was 10.9 years (IQR, 7.7-14.2 years) for control individuals without BC vs 6.6 years (IQR, 3.7-10.1 years) for patients with BC. Risk was higher in the cohort with BBD than in SEER data: BC overall (standard incidence ratio [SIR], 1.95; 95% CI, 1.76-2.17), invasive BC (SIR, 1.56; 95% CI, 1.37-1.78), and DCIS (SIR, 3.10; 95% CI, 2.54-3.77). The SIRs increased with increasing BBD severity (1.42 [95% CI, 1.19-1.71] for NP, 2.19 [95% CI, 1.88-2.54] for PDWA, and 3.91 [95% CI, 2.97-5.14] for AH), comparable to surgical cohorts with BBD. Risk also increased with increasing lesion multiplicity (SIR: 2.40 [95% CI, 2.06-2.79] for ≥3 foci of NP, 3.72 [95% CI, 2.31-5.99] for ≥3 foci of PDWA, and 5.29 [95% CI, 3.37-8.29] for ≥3 foci of AH). Ten-year BC cumulative incidence was 4.3% for NP, 6.6% for PDWA, and 14.6% for AH vs an expected population cumulative incidence of 2.9%. Conclusions and Relevance In this contemporary cohort study of women diagnosed with BBD in the percutaneous biopsy era, overall risk of BC was increased vs the general population (DCIS and invasive cancer combined), similar to that in historical BBD cohorts. Development and validation of pathologic classifications including both BBD severity and multiplicity may enable improved BC risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBreast DiseasesCarcinoma, Intraductal, NoninfiltratingPrecancerous ConditionsFemaleHumansMiddle AgedCohort StudiesRetrospective StudiesHyperplasiaBiopsyRisk Assessment

Autor:innen und Institutionen

  • Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida.
  • Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
  • Division of Epidemiology, Mayo Clinic, Rochester, Minnesota.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
  • Department of Surgery, Mayo Clinic, Rochester, Minnesota.

Förderung

  • NCI NIH HHS

Zitieren

APA

Sherman, M. E., Vierkant, R. A., Winham, S. J., Vachon, C. M., Carter, J. M., Pacheco-Spann, L., Jensen, M. R., McCauley, B. M., Hoskin, T. L., Seymour, L., Gehling, D., Fischer, J., Ghosh, K., Radisky, D. C., & Degnim, A. C. (2024). Benign Breast Disease and Breast Cancer Risk in the Percutaneous Biopsy Era. JAMA Surgery, 159(2), 193. https://doi.org/10.1001/jamasurg.2023.6382

Vancouver

Sherman ME, Vierkant RA, Winham SJ, Vachon CM, Carter JM, Pacheco-Spann L, et al. Benign Breast Disease and Breast Cancer Risk in the Percutaneous Biopsy Era. JAMA Surgery. 2024;159(2):193. doi:10.1001/jamasurg.2023.6382

BibTeX
@article{Sherman2024,
  author = {Sherman, Mark E and Vierkant, Robert A and Winham, Stacey J and Vachon, Celine M and Carter, Jodi M and Pacheco-Spann, Laura and Jensen, Matthew R and McCauley, Bryan M and Hoskin, Tanya L and Seymour, Lisa and Gehling, Denice and Fischer, Jessica and Ghosh, Karthik and Radisky, Derek C and Degnim, Amy C},
  title = {Benign Breast Disease and Breast Cancer Risk in the Percutaneous Biopsy Era},
  journal = {JAMA Surgery},
  year = {2024},
  volume = {159},
  number = {2},
  pages = {193},
  doi = {10.1001/jamasurg.2023.6382}
}
Kostenlos starten →